Abstract: A gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of canine immunoglobulin lambda chain; a gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of canine immunoglobulin kappa chain; a gene fragment which comprises a DNA sequence coding for the constant region of canine immunoglobulin gamma chain; a recombinant DNA molecule coding for an amino acid sequence of a mouse-dog chimeric antibody which comprises a gene fragment coding for an amino acid sequence of a variable region of a mouse immunoglobulin and a gene fragment coding for an amino acid sequence of a constant region of a canine immunoglobulin wherein the latter gene fragment; a polypeptide of a mouse-dog chimeric antibody which is expressed from a cell transformed with an expression vector for cells wherein said recombinant DNA molecule cording for an amino acid sequence of the mouse-dog chimeric antibody is incorporated; a dog-mouse heterohybridoma which

Abstract: A human Activated Protein C preparation with a high specific activity of 3500 U/mg or more and substantially free from thrombin or other proteases which can convert Protein C into Activated Protein C is provided. A process for preparing this human Activated Protein C, which involves, contacting a solution of human Activated Protein C, after activation of Protein C with thrombin or other activating protease, with a cation exchanger to allow for adsorption of both thrombin or another activating protease and Activated Protein C to the cation exchanger followed by elution of the human Activated Protein C alone.

Abstract: A method is disclosed for culturing animal cells in a medium characterized n that said medium contains a compound represented by the general formula ##STR1## wherein, R denotes COOM or CHO, herein M denotes hydrogen, an alkali metal or a C.sub.1 to C.sub.3 alkyl group, and n is an integer of 1 to 3.According to the present method, proliferation of animal cells can be enhanced with good reproducibility.

Abstract: A water-in-oil type oil adjuvant vaccine comprises 20 to 90% by weight of an oil phase A) which is in a liquid state at ordinary temperature; 0.5 to 30% by weight of an emulsifying agent comprising a non-ionic surfactant B) which is a partial ester derived from a polyhydric alcohol carrying at least three hydroxyl groups and a fatty acid and which is in a liquid state at 40.degree. C. and a polyoxyethylene (20 to 60 moles) hydroxy fatty acid triglyceride C); and 5 to 75% by weight of an aqueous phase D) containing a biologically acceptable and effective amount of antigens, and optionally E) 0.01 to 10% by weight of an amino acid or a salt thereof and 0.01 to 10% by weight of a non-reducing sugar or a sugar alcohol having at least 5 hydroxyl groups in the molecule. In addition, a water-in-oil-in-water type oil adjuvant vaccine comprises the foregoing water-in-oil type oil adjuvant vaccine as an internal phase and an outer aqueous phase F) comprising 0.

Abstract: A method for activating prothrombin to thrombin is presented which comprises treating an aqueous solution containing prothrombin with polyethylene glycol in the presence or absence of the calcium salt. The method enables conversion of prothrombin to thrombin in the absence of thromboplastin and allows for preparation of thrombin on an industrially large scale from easily available starting materials.

Abstract: An expression vector for the expression of an exogenous gene in an animal cell, which contains a chick .beta.-actin gene promoter and a restriction enzyme site for incorporating an exogenous gene at the downstream of said promoter and a process for expressing an exogenous gene, which comprises incorporating said exogenous gene into the expression vector at the restriction enzyme site for incorporating the exogenous gene, introducing said vector into an animal cell and culturing the obtained transformed animal cell. The expression system of the present invention can be applied to an expression of any exogenous gene and has an extremely high expression efficiency and is applicable to a wide range of host cells, and hence can sufficiently be utilized for industrial-scale production of a useful material.

Abstract: Anti-FCV (feline calicivirus) feline-type recombinant antibody effective for treatment, prevention and diagnosis of FCV infection and a gene fragment useful for preparation of said antibody are provided. Cell line 1D7 capable of producing a mouse monoclonal antibody having an excellent FCV-neutralizing activity was constructed and a gene fragment coding for the V region in charge of the FCV-specific binding of said antibody was obtained. This gene fragment and the gene coding for the constant region of the feline antibody are used to give a chimeric anti-FCV recombinant antibody. The obtained recombinant antibody is a novel antibody and is useful for the diagnosis, treatment and prevention of feline virus infections, particularly feline calicivirus infection, with high safety in administration into cats.

Abstract: The present invention relates to a gene fragment coding for a variable region of an antibody having a neutralizing activity against human immunodeficiency virus (HIV) and a process for preparing the same. A mouse-human chimeric antibody and a mouse-human reshaped antibody having a neutralizing activity against HIV can be prepared by obtaining a specific nucleotide sequence of a gene fragment coding for a variable region of H chain and L chain of an antibody having a neutralizing activity against HIV, and then artificially fusing DNAs synthesized based on these nucleotide sequences with a gene coding for a human immunoglobulin. The novel recombinant anti-HIV antibody of the present invention is useful for treatment and prevention of AIDS.

Abstract: An expression vector for the expression of an exogenous gene in an animal cell, which contains a chick .beta.-actin gene promoter and a restriction enzyme site for incorporating an exogenous gene at the downstream of said promoter and a process for expressing an exogenous gene, which comprises incorporating said exogenous gene into the expression vector at the restriction enzyme site for incorporating the exogenous gene, introducing said vector into an animal cell and culturing the obtained transformed animal cell. The expression system of the present invention can be applied to an expression of any exogenous gene and has an extremely high expression efficiency and is applicable to a wide range of host cells, and hence can sufficiently be utilized for industrial-scale production of a useful material.

Abstract: An anti-FHV-1 recombinant antibody efficacious for treatment, prevention and diagnosis of feline herpes virus-1 (FHV-1) and a gene fragment useful for preparing the same are provided. A cell producing a mouse monoclonal antibody having an excellent neutralizing activity against FHV-1 was constructed, and a gene fragment coding for V region of said antibody responsible for the specific binding activity against FHV-1 was obtained. Using this gene fragment and a gene fragment coding for the constant region of a feline antibody, a chimeric anti-FHV-1 recombinant antibody is obtained.

Abstract: A murine monoclonal antibody which specifically binds to a glycoprotein antigen having a molecular weight of about 12.times.10.sup.4 daltons (gp120) present in the envelope of human T-lymphotropic virus III.sub.MN (HTLV-III.sub.MN) and capable of neutralizing the HTLV-III.sub.MN as determined by in vitro inhibition of syncytium formation but does not bind to other HTLV-III strains, or antigen-binding fragments, which is useful for prophylaxis, treatment and diagnosis of AIDS.

Abstract: A plasmid for expression of human coagulation factor VIII H-chain, a plasmid for expression of human coagulation factor VIII L-chain, an animal cell transformed with either said H-chain expression plasmid or said L-chain expression plasmid or with both thereof, and a process for preparing a human coagulation factor VIII protein complex which comprises forming a transformed animal cell by introducing both said H-chain expression plasmid and said L-chain expression plasmid into said animal cell, culturing said cell to produce the human coagulation factor VIII protein complex in the culture medium and collecting the same. The process of the present invention allows for the production of a safe factor VIII at a high expression level applicable for the production of Factor VIII on an industrial scale.

Abstract: A novel method for production of an exogenous protein is provided, the method being suitable for expression of an exogenous protein, especially a recombinant antibody etc., in an eucaryotic cell by utilizing a genetic recombination technique. That is, a novel method for production of an exogenous protein is provided which allows for culture of a cell in which an exogenous gene is introduced in a serum-free medium and an efficient production of an exogenous protein, by using, as a host cell for expression, a fused cell which is prepared by fusing a mouse myeloma and a lymphatic cell and which can be cultured in a serum-free medium.

Abstract: A gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of canine immunoglobulin lambda chain; a gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of canine immunoglobulin kappa chain; a gene fragment which comprises a DNA sequence coding for the constant region of canine immunoglobulin gamma chain; a recombinant DNA molecule coding for an amino acid sequence of a mouse-dog chimeric antibody which comprises a gene fragment coding for an amino acid sequence of a variable region of a mouse immunoglobulin and a gene fragment coding for an amino acid sequence of a constant region of a canine immunoglobulin; a polypeptide of a mouse-dog chimeric antibody which is expressed from a cell transformed with an expression vector for cells wherein said recombinant DNA molecule cording for an amino acid sequence of the mouse-dog chimeric antibody is incorporated; a dog-mouse heterohybridoma which produces canine immunoglobulin;

Abstract: An applicator for applying a biocompatible adhesive containing human or aal protein as a principal ingredient to a surgical site of living body includes a housing to which a sterile gas is supplied, a sterile-gas supply tube connected to the housing, two adjacent sterile-gas ejecting nozzles for ejecting the sterile gas in the same direction, two adapters to which respective nozzles of syringe barrels are connected, and a pair of solution tubes, each having one end connected to the adapter and the other end protruded outwardly from the sterile gas ejection nozzle through an interior of the housing. Respective solutions supplied from the syringes via the pair of barrel adapters are ejected from the outlets of the solution tubes. The sterile gas is ejected from two sterile-gas ejection nozzles in the same direction. Consequently, the solutions are sprayed and mixed by the sterile gas, and then applied to the surgical site.

Abstract: A recombinant Marek's disease virus produced by the mutation of a Marek's disease virus with a plasmid wherein said plasmid comprises (1) a gene fragment derived from the Us region or inverted repeat sequences adjacent to both ends of said Us region of a Marek's disease virus genome and (2) an exogenous gene expression cassette incorporated in said gene fragment, said cassette comprising an exogenous gene bound downstream of a promoter derived from an animal cell or an animal virus, a process for preparing the same, a multivalent live vaccine for birds comprising the same, and a vector for administration of a physiologically active substance to birds which comprises the same.

Abstract: A Gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of feline immunoglobulin .lambda. chain; a gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of feline immunoglobulin .kappa. chain; a gene fragment which comprises a DNA sequence coding for the constant region of feline immunoglobulin .gamma.

Abstract: A culture medium without or with a low level of protein for culturing a transformed animal cell capable of continuously producing a protein prepared by using a genetic engineering technique, which contains a nonionic surfactant and cyclodextrin, and a method for producing a protein which comprises culturing a transformed animal cell capable of producing the desired protein prepared by using a genetic engineering technique in the culture medium.

Abstract: A recombinant Marek's disease virus which comprises a Marek's disease virus genom and a DNA fragment incorporated therein, said DNA fragment being constructed by incorporating a promoter derived from an animal cell or an animal virus and a structural gene coding for an exogenous protein into a gene fragment derived from a Marek's disease virus, a process for preparing the same which comprises preparing a gene fragment wherein a structural gene coding for an exogenous gene is linked to the downstream of a promoter derived from an animal cell or an animal virus, incorporating said gene fragment into a BamHI - H fragment of a gene of a Marek's disease virus type I, and incorporating said fragment into a Marek's disease virus type I genome, and a multivalent live vaccine for birds comprising the same.

Abstract: A hepatitis A, B-combined adjuvanted vaccine is disclosed in this application, said vaccine comprising an inactivated hepatitis A virus antigen, a hepatitis B virus surface antigen and an adjuvant. The present vaccine is obtained by causing the antigens to be adsorbed to the adjuvant. According to the present invention, the infection associated with hepatitis A virus and with hepatitis B virus can be prevented without causing any interference due to the mixing of these antigens and any severe side-effects, and the anti-hepatitis A virus antibody titer is greatly enhanced by the mixing.